Lusomedically

lusomedicamenta.com

How to define Lusomedicamenta? It might be simplistically stated that Lusomedicamenta is specialised in the manufacture of pharmaceutical products: solids, liquids and semi-solids. It might the be added the the company is focused on new products carrying out the management of the entire process under a key-in-hand system from product creation the the registration dossier.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

news image

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More

PHARMACY MARKET, PHARMA TECH

PANTHERX® RARE LAUNCHES DRUG FOR APDS

prnewswire | March 31, 2023

news image

PANTHERx® Rare, one of the largest and fastest growing rare pharmacies in the United States, is pleased to announce the launch of Joenja® (leniolisib), an oral selective small-molecule PI3K delta inhibitor indicated for the treatment of APDS in adult and pediatric patients ages 12 or older. "Our patients living with rare and devastating diseases deserve the best that medicine can offer. Through innovation and technology, we continue to make a positive impact on the ...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

news image

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

DECK 7 | February 04, 2020

news image

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More
news image

Pharmacy Market

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More
news image

PHARMACY MARKET, PHARMA TECH

PANTHERX® RARE LAUNCHES DRUG FOR APDS

prnewswire | March 31, 2023

PANTHERx® Rare, one of the largest and fastest growing rare pharmacies in the United States, is pleased to announce the launch of Joenja® (leniolisib), an oral selective small-molecule PI3K delta inhibitor indicated for the treatment of APDS in adult and pediatric patients ages 12 or older. "Our patients living with rare and devastating diseases deserve the best that medicine can offer. Through innovation and technology, we continue to make a positive impact on the ...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More
news image

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

DECK 7 | February 04, 2020

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us